Plain-English translation of NCT06852820 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called 177Lu-PSMA-617, a radioactive treatment designed to target liver cancer cells. The treatment works by combining a radioactive particle with a protein that attaches to cancer cells, especially the blood vessels feeding tumors. Researchers believe this medication could help people whose liver cancer has spread or cannot be removed with surgery.
Most people with advanced liver cancer have limited treatment options, and many don't respond well to existing therapies. Recent research shows that liver cancer cells often have a specific protein that this new treatment can target, but it hasn't been tested in liver cancer patients yet—making this an important first step.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the radioactive medication as an intravenous infusion (through a vein) once every 6 weeks. The study will track how well the treatment works and monitor you for side effects through blood tests and imaging scans. You'll need to visit the clinic regularly for infusions and follow-up appointments, and the trial is enrolling about 10 participants total to test whether this approach is safe and effective for liver cancer.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Melissa Lumish
Collaborators
Novartis
Enrollment target
~10 participants
Started
June 2026
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Melissa Lumish, MD
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.